Publications by authors named "C Gurioli"
Introduction: Dupilumab, a monoclonal antibody targeting IL-4 receptor subunit alpha, treats atopic dermatitis (AD) and may impact alopecia areata (AA). AA involves Th1-driven immune activity, and recent studies suggest a role for Th2 pathways. Dupilumab's effects on AA are mixed, with reports of both improvement and worsening.
View Article and Find Full Text PDFArticle Synopsis
- * In a study with 85 adults, 49.4% of patients showed at least a 90% improvement in eczema severity, while 61.2% had a favorable assessment from doctors.
- * No major safety issues were reported, and naïve patients (those who hadn't previously tried treatment) had better outcomes than those who had failed another medication, highlighting its effectiveness in real-world settings.
Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.
Elena Pezzolo Alessandra Narcisi Luigi Gargiulo Vito Di Lernia Maddalena Napolitano Carlotta Gurioli
J Am Acad Dermatol
November 2024
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.
Gianluca Avallone Francesco Cavallo Annalisa Tancredi Carlo A Maronese Martina Bertello Carlotta Gurioli
J Eur Acad Dermatol Venereol
September 2024
Article Synopsis
- A study investigated the effects of dupilumab exposure during pregnancy in women with atopic dermatitis, focusing on safety and outcomes for both mothers and infants.
- Researchers analyzed data from 19 hospitals in Italy, identifying 29 pregnant patients who used dupilumab, with the majority reporting unplanned pregnancies and stopping the medication when they learned of their pregnancy.
- The findings indicated no significant risks associated with dupilumab for adverse pregnancy or neonatal outcomes, suggesting safety for its use in early pregnancy, but further monitoring is recommended for continued use throughout pregnancy.